IP Library › Granted Patent US 7,402,601
Granted Patent B2
US 7,402,601 · App. 10/626,600 · Granted Jul 22, 2008

Pharmaceuticals for the treatment of rejection reactions in organ transplantations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,601
App. No.
10/626,600
Granted
Jul 22, 2008
Kind
B2
Abstract

The use of compound 1 and/or 2 of the formulae and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.

Claims (2)

1. A method of treating a hyperacute rejection reaction of a xenograft transplant recipient of a xenograft transplant, which comprises administering to said recipient an effective amount of a composition comprising at least one compound chosen from (a) a compound of formula 1 and (b) a compound of formula 2 and its physiologically tolerable salts:

2. The method of claim 1 , wherein the xenograft is skin, heart, kidney, liver, bone, pancreas, or blood.

Assignments (1)
CHANGE OF NAME Recorded Nov 22, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016800/0538 →